Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.44 |
| ▸ | HTR2B | P41595 | 7/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473800 | 0.89 | MEN1 (0.46) | HTR2CHTR2BHTR2AMGLLMEN1 | |
| SCHEMBL1473536 | 0.83 | RAD51 (0.45) | HTR2CMEN1KMT2AL3MBTL1PTGS2 | |
| SCHEMBL1471839 | 0.81 | FAAH (0.47) | MGLLFAAHMEN1KMT2AL3MBTL1 | |
| SCHEMBL1471885 | 0.81 | MGLL (0.54) | MGLLFAAHMEN1KMT2AL3MBTL1 | |
| SCHEMBL1471837 | 0.78 | MAPT (0.51) | HTR2CHTR2BHTR2AMGLLMEN1 | |
| SCHEMBL1471130 | 0.78 | MGLL (0.54) | MGLLFAAHMEN1KMT2AL3MBTL1 | |
| SCHEMBL1471853 | 0.75 | MGLL (0.47) | MGLLFAAHMEN1KMT2AL3MBTL1 | |
| SCHEMBL1473798 | 0.73 | KMT2A (0.41) | MGLLFAAHMEN1KMT2APTGS2 | |
| SCHEMBL1471762 | 0.71 | MAPT (0.46) | MGLLMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL1471636 | 0.71 | G6PD (0.41) | HTR2CHTR2BHTR2AMGLLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091531-B1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S R L (IT) | 2010-11-24 | — | — | EP | claimed |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2010-04-22 | — | — | US | claimed |
| EP-2091531-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | Congenia S.r.l. (IT) | 2009-08-26 | — | — | EP | claimed |
| WO-2008067863-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2008-06-12 | — | — | WO | claimed |
| WO-2016144352-A2 | THERAPEUTIC COMPOSITIONS INCLUDING ACRYLAMIDO COMPOUNDS OR PHENYL-SUBSTITUTED MALEIMIDE COMPOUNDS, VARIANTS THEREOF AND METHODS OF USING THE SAME | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2016-09-15 | — | — | WO | disclosed |
| US-7915304-B2 | Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT | CONGENIA S.R.L. (IT) | 2011-03-29 | — | — | US | disclosed |
| EP-2091531-B1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S R L (IT) | 2010-11-24 | — | — | EP | disclosed |
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2010-04-22 | — | — | US | disclosed |
| EP-2091531-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | Congenia S.r.l. (IT) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008067863-A2 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CONGENIA S.R.L. (IT) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099736-A1 | PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT | CYC1, MTPN, TXN2 | HTR2C 3384/4885HTR2B 2766/4885HTR2A 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.